Novaremed AG is a clinical-stage Swiss biopharmaceutical company, HQ in Basel, Switzerland, with a subsidiary in Israel.
Products, services, technology
Novaremed is developing an orally active, small molecule (NRD.E1) to treat Diabetic Neuropathic Pain. In a Phase 2a (PoC) study, NRD.E1 showed clinically relevant reduction in patient reported pain. Novaremed is currently preparing to conduct a global Phase 2b study expected to start in Q4 2019.
Novaremed is interested in potential partnership with pharmaceutical companies for Phase 3 development and commercialisation of its lead compound, NRD.E1.